ObjectiveTo investigate the clinical effects of levocarnitine combined with erythropoietin in the treatment of hemodialysis with renal anemia.

MethodsNinety-eight renal anemia patients with hemodialysis were randomly divided into the control group and observation group according to the digital table method(49 cases in each group).The control group was treated with erythropoietin, and the observation group was treated with levocarnitine combined with erythropoietin.The serum levels of albumin, hemoglobin, serum transferrin, hematocrit and iron metabolism index before and after treatment, and adverse reactions after drug administration were compared between two groups.

ResultsBefore treatment, the differences of the serum levels of serum ferritin, transferrin saturation, hematocrit, hemoglobin and serum albumin were not statistically significant between two groups(P>0.05).The serum levels of ferritin, transferrin saturation, hematocrit, hemoglobin and serum albumin in two groups after treatment were higher than before treatment(P < 0.05), and the serum levels in observation group were higher than those in control group(P < 0.01).The elevation of blood pressure, fever and abnormal liver and kidney functions were the main adverse reactions in two groups after treatment, and the total incidence rate of adverse reactions in observation group was lower than that in control group(P < 0.01).

ConclusionsThe levocarnitine combined with erythropoietin in treating hemodialysis renal anemia can improve the symptoms of clinical anemia, shorten the course of treatment, promote the recovery of biochemical laboratory indicators, effectively improve the cure rate, reduce complications and improve the quality of life of patients.